Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Yan Wei, Jin Zhao, Jian Ming, Xuewu Zhang & Yingyao Chen. (2022) Patient Preference for Self-Injection Devices in Rheumatoid Arthritis: A Discrete Choice Experiment in China. Patient Preference and Adherence 16, pages 2387-2398.
Read now
Read now
Catherine Bottomley, Andrew Lloyd, Gary Bennett & Nicholas Adlard. (2017) A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis. Journal of Medical Economics 20:8, pages 863-870.
Read now
Read now
José Manuel Garcia-Dominguez, Delicias Muñoz, Marta Comellas, Irmina Gonzalbo, Luis Lizán & Carlos Polanco Sánchez. (2016) Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment. Patient Preference and Adherence 10, pages 1945-1956.
Read now
Read now
Katie D Stewart, Joseph A Johnston, Louis S Matza, Sarah E Curtis, Henry A Havel, Stephanie A Sweetana & Heather L Gelhorn. (2016) Preference for pharmaceutical formulation and treatment process attributes. Patient Preference and Adherence 10, pages 1385-1399.
Read now
Read now
A. Brett Hauber, Hiep Nguyen, Joshua Posner, Iftekhar Kalsekar & James Ruggles. (2016) A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes. Current Medical Research and Opinion 32:2, pages 251-262.
Read now
Read now
Grahame Wilkinson & Michael Drummond. (2015) Alternative approaches for assessing the socioeconomic benefits of medical devices: a systematic review. Expert Review of Medical Devices 12:5, pages 629-648.
Read now
Read now
Articles from other publishers (18)
Jihad Said Inshasi, Abubaker Almadani, Sarmad Al Fahad, Suzan Ibrahim Noori, Taoufik Alsaadi, Mustafa Shakra, Ahmed Osman Shatila, Tayseer Mohammed Zein & Amir Boshra. (2020) High-efficacy therapies for relapsing-remitting multiple sclerosis: implications for adherence. An expert opinion from the United Arab Emirates. Neurodegenerative Disease Management 10:4, pages 257-266.
Crossref
Crossref
L.A. Visser, C. Louapre, C.A. Uyl-de Groot & W.K. Redekop. (2020) Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review. Multiple Sclerosis and Related Disorders 39, pages 101929.
Crossref
Crossref
Fabrice Berna, Anja S. Göritz, Guillaume Behr & Steffen Moritz. (2020) Pill or needle? Determinants of the preference for long-acting injection over oral treatment in people facing chronic illness. Progress in Neuro-Psychopharmacology and Biological Psychiatry 98, pages 109798.
Crossref
Crossref
Marcel F. Jonker, Bas Donkers, Lucas M.A. Goossens, Renske J. Hoefman, Lea J. Jabbarian, Esther W. de Bekker-Grob, Matthijs M. Versteegh, Gerard Harty & Schiffon L. Wong. (2020) Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment Options. Medical Decision Making 40:2, pages 198-211.
Crossref
Crossref
Christine Poulos, Craig Wakeford, Elizabeth Kinter, Brennan Mange, Thomas Schenk & Mehul Jhaveri. (2020) Patient and physician preferences for multiple sclerosis treatments in Germany: A discrete-choice experiment study. Multiple Sclerosis Journal - Experimental, Translational and Clinical 6:1, pages 205521732091077.
Crossref
Crossref
Leslie Wilson, Lawrence Lin & Kuldev Singh. (2019) The Patient Perspective: Putting the Patient at the Center of the Translational Innovation Process. Clinical Pharmacology & Therapeutics 107:1, pages 82-84.
Crossref
Crossref
Vikas Soekhai, Esther W. de Bekker-Grob, Alan R. Ellis & Caroline M. Vass. (2018) Discrete Choice Experiments in Health Economics: Past, Present and Future. PharmacoEconomics 37:2, pages 201-226.
Crossref
Crossref
Farimah Rahimi, Hamid Reza Rasekh, Ezatollah Abbasian & Farzad Peiravian. (2018) A new approach to pharmaceutical pricing based on patients’ willingness to pay. Tropical Medicine & International Health 23:12, pages 1326-1331.
Crossref
Crossref
Edward J. D. Webb, David Meads, Ieva Eskyte, Natalie King, Naila Dracup, Jeremy Chataway, Helen L. Ford, Joachim Marti, Sue H. Pavitt, Klaus Schmierer & Ana Manzano. (2018) A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis. The Patient - Patient-Centered Outcomes Research 11:4, pages 391-402.
Crossref
Crossref
Farimah Rahimi, Hamid Reza Rasekh, Ezatollah Abbasian, Farzad Peiravian, Masoud Etemadifar, Fereshteh Ashtari, Ali Mohammad Sabzghabaee & Mohammad Reza Amirsadri. (2018) Patient preferences for Interferon-beta in Iran: A discrete choice experiment. PLOS ONE 13:3, pages e0193090.
Crossref
Crossref
Christine Poulos, Elizabeth Kinter, Johan van Beek, Katrine Christensen & Joshua Posner. (2018) PREFERENCES OF PATIENTS WITH MULTIPLE SCLEROSIS FOR ATTRIBUTES OF INJECTABLE MULTIPLE SCLEROSIS TREATMENTS IN THE UNITED KINGDOM AND FRANCE. International Journal of Technology Assessment in Health Care 34:4, pages 425-433.
Crossref
Crossref
Ana L. HincapieJonathan PenmCraig F. Burns. (2017) Factors Associated with Patient Preferences for Disease-Modifying Therapies in Multiple Sclerosis. Journal of Managed Care & Specialty Pharmacy 23:8, pages 822-830.
Crossref
Crossref
Carol Mansfield, Nina Thomas, David Gebben, Maria Lucas & A. Brett Hauber. (2017) Preferences for Multiple Sclerosis Treatments. International Journal of MS Care 19:4, pages 172-183.
Crossref
Crossref
Lei Qin, Stephanie Chen, Emuella Flood, Alka Shaunik, Beverly Romero, Marie de la Cruz, Cynthia Alvarez & Susan Grandy. (2017) Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom. Diabetes Therapy 8:2, pages 335-353.
Crossref
Crossref
Pei-Jung Lin, Cayla J. Saret, Peter J. Neumann, Eileen A. Sandberg & Joshua T. Cohen. (2016) Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation Study. PharmacoEconomics 34:12, pages 1255-1265.
Crossref
Crossref
Christine Poulos, Elizabeth Kinter, Jui-Chen Yang, John F. P. Bridges, Joshua Posner & Anthony T. Reder. (2015) Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment. The Patient - Patient-Centered Outcomes Research 9:2, pages 171-180.
Crossref
Crossref
Christine Poulos, Elizabeth Kinter, Jui-Chen Yang, John F. P. Bridges, Joshua Posner, Erika Gleißner, Axel Mühlbacher & Bernd Kieseier. (2016) A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany. Therapeutic Advances in Neurological Disorders 9:2, pages 95-104.
Crossref
Crossref
Paul Wicks, David Brandes, Jinhee Park, Dimitri Liakhovitski, Tatiana Koudinova & Rahul Sasane. (2015) Preferred Features of Oral Treatments and Predictors of Non-Adherence: Two Web-Based Choice Experiments in Multiple Sclerosis Patients. interactive Journal of Medical Research 4:1, pages e6.
Crossref
Crossref